» Articles » PMID: 8662795

Differential Activation of Acute Phase Response Factor/Stat3 and Stat1 Via the Cytoplasmic Domain of the Interleukin 6 Signal Transducer Gp130. II. Src Homology SH2 Domains Define the Specificity of Stat Factor Activation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1996 May 31
PMID 8662795
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Distinct yet overlapping sets of STAT transcription factors are activated by different cytokines. One example is the differential activation of acute phase response factor (APRF, also called Stat3) and Stat1 by interleukin 6 and interferon-gamma. Interleukin 6 activates both factors while, at least in human cells, interferon-gamma recruits only Stat1. Stat1 activation by interferon-gamma is mediated through a cytosolic tyrosine motif, Y440, of the interferon-gamma receptor. In an accompanying paper (Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 12991-12998), we demonstrated that two tyrosine motifs within the cytoplasmic part of the interleukin 6 signal transducer gp130 specifically mediate APRF activation while two others can recruit both APRF and Stat1. By expressing a series of Stat1/APRF domain swap mutants in COS-7 cells, we now determined which domains of Stat1 and APRF are involved in the specific recognition of phosphotyrosine motifs. Our data demonstrate that the SH2 domain is the sole determinant of specific STAT factor recruitment. Furthermore, the SH2 domain of Stat1 is able to recognize two unrelated types of phosphotyrosine motifs, one represented by the interferon-gamma receptor Y440DKPH peptide, and the other by two gp130 YXPQ motifs. By molecular modeling, we propose three-dimensional model structures of the Stat1 and APRF SH2 domains which allow us to explain the different binding preferences of these factors and to predict amino acids crucial for specific peptide recognition.

Citing Articles

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.

Wang W, Lopez McDonald M, Hariprasad R, Hamilton T, Frank D Cancers (Basel). 2024; 16(7).

PMID: 38611065 PMC: 11011165. DOI: 10.3390/cancers16071387.


The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.

ONeill C, Sun K, Sundararaman S, Chang J, Glynn S Front Physiol. 2024; 15:1358850.

PMID: 38601214 PMC: 11004480. DOI: 10.3389/fphys.2024.1358850.


Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis.

Shkhyan R, Flynn C, Lamoure E, Sarkar A, Van Handel B, Li J Sci Transl Med. 2023; 15(688):eabq2395.

PMID: 36947594 PMC: 10792550. DOI: 10.1126/scitranslmed.abq2395.


Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.

de Souza P, Henning P, Lerner U Int J Mol Sci. 2022; 23(6).

PMID: 35328707 PMC: 8953253. DOI: 10.3390/ijms23063287.


STAT3 Role in T-Cell Memory Formation.

Kaminskiy Y, Melenhorst J Int J Mol Sci. 2022; 23(5).

PMID: 35270020 PMC: 8910982. DOI: 10.3390/ijms23052878.